MosaiQ™ by Quotient
MosaiQ aims to become the world’s first fully automated and consolidated testing platform for both blood grouping and transfusion transmitted infectious disease screening of donor blood. MosaiQ harnesses traditional serology and advanced microarray technology to deliver safe and comprehensive antigen typing and blood-group antibody detection.
Quotient’s dedication to transfusion diagnostics is supported by over 30 years of experience in the field. Our strong heritage and focus enable us to create innovative solutions that anticipate and address our customers’ needs.
The MosaiQ platform provides:
Rapid results: 35 minutes to first sample result. Subsequent sample results every 24 seconds.
Advanced processing: real-time resource management
The heart of this ground-breaking technology is the MosaiQ microarray, a miniaturized technology for blood grouping and disease screening.
Each microarray contains up to 132 probes, offering unparalleled testing capability.
The MosaiQ immunohematology (IH) microarray delivers comprehensive red cell antigen typing and a vast array of red cells for antibody detection and exclusion.
The MosaiQ serological disease screening (SDS) microarray provides full mandatory donor serological disease screening capability.
The MosaiQ molecular disease screening (MDS) microarray is being developed to provide donor molecular disease screening.